CD19 Chimeric Antigen Receptor (CAR) T- Cell therapy with Tisagenlecleucel in Children with B-Cell Acute Lymphoblastic Leukemia: Preliminary Findings from a Tertiary Care Center

Introduction: (CAR) T-cell therapy is an evolving therapy in children with relapsed/refractory B-Cell acute lymphoblastic leukemia (ALL). Methodology:We describe the outcome of 13 children who was treated with Tisagenlecleucel in our center from January 2023 to December 2024.The indication of treatment, T-cell collection and manufacturing met institutional criteria and commercial quality specifications.All patient received similar supportive therapy, lymphodepletion regimen and monitored in the hospital for at least 14 days post-infusion.Cytokine release syndrome (CRS) and Immune effector cell associated neurotoxicity (ICANS) was graded and managed per ASTCT guidelines.